These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9552055)

  • 1. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
    Alexander HR; Bartlett DL; Libutti SK; Fraker DL; Moser T; Rosenberg SA
    J Clin Oncol; 1998 Apr; 16(4):1479-89. PubMed ID: 9552055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
    Libutti SK; Barlett DL; Fraker DL; Alexander HR
    J Am Coll Surg; 2000 Nov; 191(5):519-30. PubMed ID: 11085732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
    Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.
    Alexander HR; Libutti SK; Pingpank JF; Bartlett DL; Helsabeck C; Beresneva T
    Ann Surg Oncol; 2005 Feb; 12(2):138-44. PubMed ID: 15827794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Pingpank JF; Steinberg SM; Bartlett DL; Helsabeck C; Beresneva T
    Clin Cancer Res; 2003 Dec; 9(17):6343-9. PubMed ID: 14695133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
    Bartlett DL; Libutti SK; Figg WD; Fraker DL; Alexander HR
    Surgery; 2001 Feb; 129(2):176-87. PubMed ID: 11174711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.
    Lans TE; Bartlett DL; Libutti SK; Gnant MF; Liewehr DJ; Venzon DJ; Turner EM; Alexander HR
    Clin Cancer Res; 2001 Apr; 7(4):784-90. PubMed ID: 11309322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms.
    Grover AC; Libutti SK; Pingpank JF; Helsabeck C; Beresnev T; Alexander HR
    Surgery; 2004 Dec; 136(6):1176-82. PubMed ID: 15657573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
    Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
    Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.
    Lindnér P; Fjälling M; Hafström L; Kierulff-Nielsen H; Mattsson J; Scherstén T; Rizell M; Naredi P
    Eur J Surg Oncol; 1999 Apr; 25(2):179-85. PubMed ID: 10218462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver.
    Rothbarth J; Pijl ME; Vahrmeijer AL; Hartgrink HH; Tijl FG; Kuppen PJ; Tollenaar RA; van de Velde CJ
    Br J Surg; 2003 Nov; 90(11):1391-7. PubMed ID: 14598420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease.
    Mocellin S; Pilati P; Da Pian P; Forlin M; Corazzina S; Rossi CR; Innocente F; Ori C; Casara D; Ujka F; Nitti D; Lise M
    Ann Surg Oncol; 2007 Feb; 14(2):802-9. PubMed ID: 17103263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
    Alexander HR; Brown CK; Bartlett DL; Libutti SK; Figg WD; Raje S; Turner E
    Clin Cancer Res; 1998 Oct; 4(10):2357-62. PubMed ID: 9796965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
    De Vries MR; Borel Rinkes IH; Swaak AJ; Hack CE; Van De Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Eggermont AM
    Eur J Clin Invest; 1999 Jun; 29(6):553-60. PubMed ID: 10354218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.
    de Vries MR; Borel Rinkes IH; van de Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Vahrmeijer AL; Eggermont AM
    Recent Results Cancer Res; 1998; 147():107-19. PubMed ID: 9670273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
    Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
    Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
    Borel Rinkes IH; de Vries MR; Jonker AM; Swaak TJ; Hack CE; Nooyen PT; Wiggers T; Eggermont AM
    Br J Cancer; 1997; 75(10):1447-53. PubMed ID: 9166936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.